Bayer will present three new prespecified subgroup analyses from the pivotal Phase III FINEARTS-HF cardiovascular outcomes trial investigating KERENDI ...
The flow cytometry-based assay measures the expression of the protein FcyR11a as a biomarker for cardiovascular risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback